Sanofi Collaborates with Denali for its RIPK1 Programme
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)
Published: 14 Nov-2018
DOI: 10.3833/pdr.v2018.i11.2371 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing to look at external innovation to bolster its pipeline, Sanofi has paid Denali Therapeutics US$125 M upfront for its receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors for the treatment of neurological and systemic inflammatory diseases, including Alzheimer’s disease, multiple sclerosis and rheumatoid arthritis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS